l e t t e r s Allergen-specific immunoglobulin E (present in allergic sensitization) has a central role in the pathogenesis of allergic disease. We performed the first large-scale genome-wide association study (GWAS) of allergic sensitization in 5,789 affected individuals and 10,056 controls and followed up the top SNP at each of 26 loci in 6,114 affected individuals and 9,920 controls. We increased the number of susceptibility loci with genome-wide significant association with allergic sensitization from three to ten, including SNPs in or near TLR6, C11orf30, STAT6, SLC25A46, HLA-DQB1, IL1RL1, LPP, MYC, IL2 and HLA-B. All the top SNPs were associated with allergic symptoms in an independent study. Risk-associated variants at these ten loci were estimated to account for at least 25% of allergic sensitization and allergic rhinitis. Understanding the molecular mechanisms underlying these associations may provide new insights into the etiology of allergic disease.
The effort to identify genes for atopic diseases is limited both by the heterogeneity of these diseases 2 and by diagnostic uncertainty. An alternative approach is to study an intermediate phenotype, such as allergic sensitization. This sensitization is likely to be more closely related to a specific physiological mechanism and thereby to the genetic substrate, and it is clearly defined on the basis of objective, standardized assessments. It may, therefore, be a more powerful phenotype in genetic studies. Insight into the genetics of sensitization would also increase understanding of the shared genetic basis for sensitization and atopic diseases, thus also enhancing understanding of their causal relationship.
Allergic sensitization has an estimated heritability of 0. 40-0.85 (refs. 3,4) . Heritability seems higher for a general tendency for sensitization (sensitization against any allergen) than for sensitization against one specific allergen 5 . Many candidate genes have been reported 6 , but few have been firmly established. The first GWAS on allergic sensitization 7 identified three putative susceptibility loci (5q22.1 near TMEM232, 11q13.5 near C11orf30 and the human leukocyte antigen (HLA) region) but considered only sensitization to a single allergen (grass), was based on a modest sample size and did not include replication.
We conducted a two-stage GWAS meta-analysis of allergic sensitization including data from 16 studies from the EArly Genetics and Lifecourse Epidemiology (EAGLE) Consortium and the Australian l e t t e r s Asthma Genetics Consortium (AAGC). Sensitization status was assessed objectively and was defined by either elevated levels of allergen-specific IgE in blood or a positive skin reaction after puncture of the skin through a droplet of allergen extract (skin prick test, SPT).
Sensitization status was assessed for common food and inhalant allergens (Supplementary Tables 1-3).
The stage 1 discovery phase included 5,789 individuals who were sensitized (cases) and 10,056 who were not sensitized (controls). In silico and de novo replication of the top SNP from each of the 26 loci with associations in stage 1 included up to 6,114 independent cases and 9,920 independent controls, all of European descent.
In stage 1, meta-analysis was performed on results after applying studyspecific genomic control adjustment. There was minimal overall evidence of population stratification or other unaccounted biases on the full sample set (λ GC = 1.01). We detected an excess of association signals beyond those expected by chance (Supplementary Fig. 1 ), with SNPs in five regions reaching genome-wide significance (P < 5 × 10 −8 ; Fig. 1 and Table 1 ). These 5 loci and 21 with suggestive evidence of association (P < 1 × 10 −5 ) were selected for replication in stage 2.
In stage 2, 10 of the 26 loci showed evidence of association (P < 0.05) and directional consistency with results from stage 1. All ten loci had associations that reached genome-wide significance in the combined meta-analysis ( Table 1, Supplementary  Figs. 2,3 and Supplementary Table 4 ). There was no statistically significant modification of effects by age, assessment method (SPT or blood IgE levels) or sex after adjustment for multiple comparisons.
All 10 genome-wide significant SNPs in our study showed evidence of association (P < 0.005) with self-reported allergy symptoms in an independent companion study 8 including more than 53,000 individuals ( Table 1 and Supplementary Table 5 ). These findings suggest that these loci increase not only the risk of sensitization but also that of allergic disease.
To provide insight into the molecular mechanisms underlying each of the ten associations, we searched for cis-acting expression quantitative trait loci (eQTLs) using gene expression data obtained from six cell types or tissues (white blood cells (WBCs), lymphoblastoid cell lines (LCLs), whole blood, adipose tissue, B cells and monocytes 9 ). At nine of the ten loci, the sentinel SNP was associated (P < 0.001) with the expression of one or more nearby genes (within 1 Mb of Table 9 ). Taken together, these results suggest that, at these ten associated loci, the underlying causal variant(s) is likely to influence DNA transcription and/or mRNA degradation. Using data from the 1000 Genomes Project, we also identified missense variants in high LD with the sentinel SNPs in TLR1 at 4p14 and MICA at 6p21.32 (Supplementary Table 10 ). The 8q24 region does not include any gene previously implicated in allergic disease or related traits. The lead SNP, rs4410871, is located in the PVT1 transcript downstream of the MYC gene. MYC is a transcription factor involved in multiple cellular processes, including cell growth, differentiation and apoptosis in lymphocytes, and has an established role in several cancers, including B cell malignancies 10 . PVT1 is a noncoding RNA that hosts several microRNAs 11 , which have been suggested to be as important as MYC in T cell activation 12 . The same variant (rs4410871) was reported to associate with multiple sclerosis, with the risk allele in our study (T) being the protective allele for multiple sclerosis 13 .
The 11q13.5 and 5q22.1 loci do not harbor any genes with an established role in the immune system. However, both loci were identified recently in a GWAS of allergic sensitization 7 , and the 11q13.5 locus seems to have pleiotropic effects of importance in the development of both atopic disease 7, 14, 15 and autoimmune disease 16, 17 . The correlation structure and previous findings in the 5q22.1 region suggest that this region harbors several independent loci for atopic traits and that our top SNP represents a new risk variant (Supplementary  Table 11 and Supplementary Note).
The 4p14 locus harbors the genes encoding Toll-like receptor 1 (TLR1), TLR6 and TLR10. This locus was associated with asthma and IgE levels in candidate gene studies [18] [19] [20] . Toll-like receptors are pattern-recognition molecules involved in innate immunity and immune responses to microbial exposure 21 . The top SNP at this locus showed evidence of heterogeneity between studies. This may indicate modification of its effect by environmental factors and points to a focus for future gene-environment interaction studies.
The six remaining loci with genome-wide significant association all implicate genes with established roles in the immune system, including STAT6 (ref. 22 To explore biological connections and potentially identify new pathways associated with allergic sensitization, we applied gene set enrichment analysis (MAGENTA) 31 to the discovery-stage GWAS results and identified significant enrichment of 11 partially overlapping gene sets ( Fig. 2 and Supplementary Table 12 ). These results suggest the enrichment of two cohesive clusters of biologically related gene sets. The largest cluster included gene sets related to immune function, all sharing multiple genes, suggesting a broad overlap between autoimmunity and allergy ( Supplementary Fig. 4) . The second cluster included potentially new sensitization pathways, such as PTEN signaling, ephrin receptor signaling and insulin growth factor (IGF)-1 signaling, all characterized by involvement in cell growth and cancer. Three of 19 SNPs not in LD (r 2 < 0.1) with the loci identified in our discovery GWAS (in PTPN11, IL5 and CD86; Supplementary Table 13 ) showed evidence of association (P < 0.05) with self-reported allergy in the companion paper 8 , suggesting that these are true, albeit weaker, allergy susceptibility loci.
To further highlight biological connections between genes located within the ten loci with genome-wide significant associations, we applied the GRAIL pathway analysis tool 32 and identified biologically connected genes related to immune function. Notably, we found that STAT6, TLR6, IL18RAP and HLA-DQB1 were interrelated, and expression of these genes was associated with the top SNPs, suggesting their involvement in a common mechanism that is likely to be causally associated with sensitization ( Supplementary Fig. 5) .
We tested the potential use of the ten sensitization-associated loci in determining asthma or eczema risk by testing for association with these diseases in two large published GWAS 33, 34 . There was evidence of association with asthma with directional consistency for nine of the ten SNPs (Supplementary Table 14) . This overlap was considerably greater than the previously reported minimal overlap between total IgE levels and asthma-associated gene variants 33 , consistent with a potentially causal role for sensitization in the pathogenesis of asthma. In eczema, the associations were weaker but had consistent directions of effect (Supplementary Table 15 ).
Our analysis also provided the opportunity to investigate whether previously reported susceptibility loci for atopic diseases and related intermediate phenotypes are associated with allergic sensitization (Supplementary Tables 16 and 17) . Many reported atopy-related genes were associated with sensitization. However, several loci strongly associated with total IgE levels, such as FCER1A and HLA-A, as well as loci strongly associated with asthma, such as the 17q12-21 locus and IL33, were only weakly or not significantly associated with sensitization, suggesting that these loci increase asthma risk by mechanisms other than allergic sensitization.
Lastly, we estimated the proportion of allergic sensitization in the general population caused by the ten identified loci (Supplementary Table 18 ). We obtained a conservative population-attributable risk fraction estimate above 25% by considering the 10% of the population with the lowest risk scores to represent an 'unexposed' group. Results were similar for allergic rhinitis, which is the strongest clinical correlate of sensitization. The capacity to predict individual risk was limited (Supplementary Note). Sensitization prevalence plotted by genetic risk score (Fig. 3) showed approximately two times higher npg l e t t e r s prevalence of sensitization in the 9.2% of the population with the highest genetic risk scores compared to the 7.6% of the population with the lowest risk scores. Several of the identified loci for sensitization are also reported susceptibility loci for autoimmune disease (Supplementary Table 19) . We observed examples both of opposing directions of effect (for multiple sclerosis at the MYC-PVT1 locus) and the same direction of effect (for diabetes and Crohn's disease at the IL2 and C11orf30 loci) relative to the effects observed in sensitization. Allergic and autoimmune disorders are classically described as representatives of helper T cell type 1 (T H 1) and type 2 (T H 2) immunity associated with the production of cross-regulatory cytokines. Our results suggest that the T H 1 and T H 2 paradigm 35 does not adequately explain the relationship between these disorders.
In conclusion, we increased the number of established susceptibility loci for allergic sensitization from three to ten, which contribute substantially to the population-attributable risk fraction. Understanding the molecular mechanisms underlying associations with these sequence variants may provide new insights into the etiology of allergy and other immune diseases.
URLs. MaCH, http://www.sph.umich.edu/csg/abecasis/MACH/ download/1000G-PhaseI-Interim.html; HaploReg, http://www. broadinstitute.org/mammals/haploreg/haploreg.php; GHS_Express, http://genecanvas.ecgene.net/uploads/ForReview/.
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Phenotype definition. We studied the general tendency of allergen-specific IgE production without restriction by assessment method or allergen. Cases were defined as individuals with objectively measured sensitization against at least one of the allergens tested for in the respective studies, and controls were defined as individuals who were not sensitized against any of the allergens tested ( Supplementary Tables 1 and 2) . We included sensitization assessed by skin reaction after puncture of the skin with a droplet of allergen extract (SPT) and/or by detection of the levels of circulating allergen-specific IgE in the blood. The SPT wheal diameter cutoffs were 3 mm larger than the negative control for cases and smaller than 1 mm for controls. To optimize case specificity and the correlation between methods, we chose a high cutoff of specific IgE levels for cases (3.5 IU/ml) and a low cutoff for controls (0.35 IU/ml). We combined data from children and adults but chose a lower age limit of 6 years, as sensitization status at younger ages shows poorer correlation with sensitization later in life, both owing to transient sensitization and frequent development of sensitization during late childhood.
Discovery analysis. The discovery analysis was based on 5,798 individuals who were sensitized (cases) and 10,056 controls of European descent from 10 studies. Individual studies were approved by the local research ethics committees, and informed consent was obtained from all participants when necessary. Details on sample recruitment as well as phenotypes and summary details for each collection are given in the Supplementary Note and in Supplementary Tables 1 and 2 . Genome-wide genotyping was performed independently in each cohort with the use of various standard genotyping technologies (Supplementary Table 3 and Supplementary Note). Imputation was independently conducted for each study with reference to HapMap phase 2 or 3 CEU genotypes (Utah residents of Northern and Western European ancestry), and association analysis was performed using logistic regression models based on an expected allelic dosage model for SNPs, adjusting for ancestry-informative principal components as necessary. SNPs with minor allele frequency (MAF) of <1% and/or poor imputation quality (r 2 < 0.3, if using the imputation algorithm MaCH, or proper info <0.4, if using the IMPUTE imputation algorithm) were excluded. After genomic control at the level of the individual studies, we performed meta-analysis of association data for ~2.5 million imputed and genotyped autosomal SNPs using additive model fixed-effects meta-analysis as implemented in METAL (version 2010-08-01). For a given SNP, study-specific effect size estimates (transformed to z scores by METAL) were weighted inversely with their variance.
Replication analysis. We selected for replication the most strongly associated SNP in each of the 26 most strongly associated loci in the discovery metaanalysis (all with P < 1 × 10 −5 in stage 1; Table 1 and Supplementary Table 4) . These SNPs were analyzed using in silico data from six studies with GWAS data not included in the discovery meta-analysis and de novo genotyping data from three additional studies (Supplementary Tables 1-3) . The largest possible replication sample size amounted to 6,114 cases and 9,920 controls from 9 studies, all of European descent. Association analyses were again conducted for each study using a logistic regression model with similar covariate adjustments, based on expected allelic dosage for the in silico studies and allele counts in the de novo genotyping studies. We applied a threshold of P < 5 × 10 −8 for genome-wide significance. Informed consent was obtained from all parents (and children, when appropriate) participating in the individual studies, which were approved by the respective ethics committee. Details can be found in the Supplementary Note.
Association and Manhattan plots. The LocusZoom tool was used to generate association plots with the 400-kb region centered on the index SNP 36 . Manhattan plots were generated with R Bioconductor software.
Functional annotation.
To help identify the potential causal gene(s) underlying each of the ten associations, we searched for cis eQTLs using gene expression results obtained from in-house data sets of four cell types or tissues: WBCs, LCLs, whole blood and adipose tissue.
Avon Longitudinal Study of Parents and Children (ALSPAC)
. mRNA quantified expression data were collected for 947 unrelated ALSPAC participants from LCLs established from blood samples taken when the children were 9 years old. All cell lines were from a first passage. Cells were harvested when confluent, washed in PBS and frozen in RNAlater (Ambion, Life Technologies). RNA was extracted using the Qiagen RNeasy extraction kit and amplified using the Illumina TotalPrep-96 RNA Amplification kit. Expression was surveyed using Illumina HT-12 v3 BeadChip arrays. Expression data from ALSPAC are available upon request in accordance with the ALSPAC data sharing policy (http://www.bris.ac.uk/alspac/researchers/data-access/policy/). Each individual sample was run with two replicates. Expression data were normalized by quantile normalization between replicates and then by median normalization across individuals.
KORA. Expression analysis in this study was based on whole-blood samples of KORA (Cooperative Health Research in the Region of Augsburg) F4 participants aged 62 to 81 years 37 . Gene expression profiling was performed on RNA isolated from whole blood using the Illumina HumanHT-12 v3 BeadChip as described elsewhere 38 (deposited at ArrayExpress under accession E-MTAB-1174).
deCODE. Expression analyses were based on WBCs (n = 745) and adipose tissue (n = 600) from randomly selected Icelandic individuals. Gene expression profiling was performed as previously described 39 (deposited in the Gene Expression Omnibus (GEO) under accessions GSE7965 and GPL3991).
B cell and monocyte eQTL study. Expression quantitative trait analysis was performed on gene expression data from CD14 + monocyte (n = 282) and CD19 + B cell samples that were positively selected from freshly purified peripheral blood mononuclear cell fractions as previously described 40 (deposited at ArrayExpress under accession EGAD00010000144). Genotyping data for these European individuals were generated using HumanOmniExpress12v1.0 BeadChips (Illumina), with whole-genome imputation performed using IMPUTE2 against the 1000 Genomes Project phase I integrated variant set (March 2012). Expression data were obtained using HumanHT-12 v4 BeadChips (Illumina), with variance-stabilizing transformation and robust spline normalization between chips performed using the R package lumi 41 . To identify putative cis eQTLs, linear analysis was performed using Matrix eQTL 42 with a 1-Mb window between each SNP and probe and with the first 15 principal components of the expression data included as covariates.
Furthermore, we used publicly available bioinformatics resources to annotate putative associations with gene expression, coding SNPs and regulatory elements. We annotated SNPs in LD (r 2 > 0.8, within 2 Mb) with the top SNP from each of the genome-wide significant loci on the basis of 1000 Genomes Project Interim Phase I data (b37) from 381 Europeans. Chromosomal positions were compared against UCSC dbSNP132 (hg19) to find alternative SNP IDs (for example, chromosome 4: 38,774,337 to rs111437368). Regulatory elements were annotated by HaploReg in terms of predicted ENCODE chromatin state (promoter and enhancer histone modification signals) and DNase I hypersensitivity. We used the GHS_Express database 9 to identify variants associated (P < 1 × 10 −5 ) with gene expression levels (eQTL) and in LD (r 2 > 0.3) with the ten top SNPs; the RefGene tract of the UCSC Genome Browser was used for gene annotation.
Population-attributable risk fractions (PARFs).
Population-attributable risk fractions were estimated from three large general-population samples: B58C (participant ages of 44-45 years), Health2006 (participant ages of 18-69 years) and ALSPAC (participant age of 7.5 years). Health2006 and the B58C subsample used for this purpose were part of the replication stage only, whereas ALSPAC samples were part of both the discovery and replication stages. Within each cohort, a genetic risk score was calculated by applying the pooled perallele coefficients (ln(OR) values) from the replication sets to the number of higher-risk alleles of each of the ten genome-wide significant loci (one SNP per locus). Population-attributable risk fractions were estimated in two ways. First, the prevalence of sensitization at a genetic risk score of zero (no higher-risk alleles for any of the ten SNPs) was predicted, with 95% confidence intervals, from the intercept term in a logistic regression model with risk score as a continuous explanatory variable. Each population-attributable risk fraction was then derived (with 95% confidence interval) by expressing the difference between the observed prevalence and the predicted (unexposed) prevalence as a percentage of the observed prevalence. Second, because there were no individuals observed with zero higher-risk alleles, the prevalence of sensitization npg for individuals in the lowest decile of the genetic risk score distribution was estimated in a similar manner and was used to derive population-attributable risk fraction on the assumption that this 10% of the population was unexposed. The second method has the advantage that it does not predict beyond the bounds of the data, but its results are conservative compared to those from the first method. Population-attributable risk fractions were estimated for sensitization measured by SPT and specific IgE levels (cutoffs of 0.35 and 3.5 IU/ml) and for allergic rhinitis.
Pathway enrichment analyses. MAGENTA pathway analysis. To explore potentially new pathways associated with allergic sensitization in the full GWAS data set, we applied an adaption of gene set enrichment analysis (metaanalysis gene set enrichment of variant associations, MAGENTA version 2) 31 . Briefly, each gene in the genome was mapped to a single SNP with the lowest P value within a 110-kb window upstream or a 40-kb window downstream of the SNP. Gene P values were corrected for confounding factors, such as gene size, LD patterns, SNP density and other genetic factors. Adjusted P values were ranked, and the observed number of genes in a given pathway above a given significance threshold (95th percentile) was calculated. This statistic was compared with that generated with 10,000 randomly permuted pathways of identical size to generate an empirical gene set enrichment analysis P value for each pathway. In our study, individual pathways that reached FDR < 0.01 were deemed significant, and, unless otherwise stated, results for the 95th-percentile cutoff analysis are reported.
To identify the degree of overlap between gene sets, we plotted an enrichment map of the significant pathways. An enrichment map is a network where vertices represent pathways, vertex size is proportional to the number of genes and edge width represents the number of genes shared by two pathways. Vertices are colored according to enrichment FDR. To further identify which significant pathways were central, we plotted a bipartite network of significant genes (adjusted P < 0.0273) connected to their corresponding pathways.
GRAIL pathway analysis. GRAIL 32 was run with gene size correction enabled and was based on PubMed abstracts for papers published in or before December 2006. We specified genes at each of the ten validated loci explicitly by considering all genes within the 1-Mb flanking region on each side of the given lead SNP. The VIZ-GRAIL tool 43 was used to visualize the GRAIL results.
